• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MBI’s Optison approved in Europe

Article

Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the

Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the European Union, with sales to begin first in Germany, Austria, and the U.K.

MBI this month also announced financial results for the fourth quarter (end-March) that showed the impact of Optison sales in the U.S., which began in January (SCAN 1/14/98). MBI’s Optison sales to Mallinckrodt totaled $700,000, exceeding the company’s expectations. MBI’s total revenues for the period were $2 million, compared with sales of $1.5 million in the fourth quarter of 1996. MBI had a net loss of $5.9 million in the most recent period, compared with a net loss of $4.3 million in the fourth quarter of 1996.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.